Search

Your search keyword '"Vestjens, J. H."' showing total 8 results
Start Over Author "Vestjens, J. H."
8 results on '"Vestjens, J. H."'

3. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

Author

Kwakman, Johannes J.M., Vink, G., Vestjens, J. H., Beerepoot, L. V., de Groot, J. W., Jansen, R. L., Opdam, F. L., Boot, H., Creemers, G. J., van Rooijen, J. M., Los, M., Vulink, A. J.E., Schut, H., van Meerten, E., Baars, A., Hamberg, P., Kapiteijn, E., Sommeijer, D. W., Punt, C. J.A., Koopman, M., Kwakman, Johannes J.M., Vink, G., Vestjens, J. H., Beerepoot, L. V., de Groot, J. W., Jansen, R. L., Opdam, F. L., Boot, H., Creemers, G. J., van Rooijen, J. M., Los, M., Vulink, A. J.E., Schut, H., van Meerten, E., Baars, A., Hamberg, P., Kapiteijn, E., Sommeijer, D. W., Punt, C. J.A., and Koopman, M.

Abstract

BACKGROUND The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands. METHODS Medical records of patients from 17 centers treated in the trifluridine/tipiracil compassionate use program were reviewed and checked for RECOURSE eligibility criteria. Baseline characteristics, safety, and survival times were compared, and prespecified baseline characteristics were tested in multivariate analyses for prognostic significance on overall survival (OS). RESULTS A total of 136 patients with a median age of 62 years were analyzed. Forty-three patients (32%) did not meet the RECOURSE eligibility criteria for not having received all prior standard treatments (n = 35, 26%) and/or ECOG performance status (PS) 2 (n = 12, 9%). The most common grade ≥3 toxicities were neutropenia (n = 44, 32%), leukopenia (n = 8, 6%), anemia (n = 7, 5%), and fatigue (n = 7, 5%). Median progression-free survival (PFS) and median OS were 2.1 (95% CI, 1.8-2.3) and 5.4 months (95% CI, 4.0-6.9), respectively. Patients with ECOG PS 2 had a worse median OS (3.2 months) compared to patients with ECOG PS 0-1 (5.9 months). ECOG PS, KRAS-mutation status, white blood cell count, serum lactate dehydrogenase, and alkaline phosphatase were prognostic factors for OS. CONCLUSIONS Our data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Differences in patient characteristics between our population and the RECOURSE study population should be taken into account in the interpretation of survival data. Our results argue against the use of trifluridine/tipiracil in patients with ECOG PS 2. FUNDING Johannes J.M. Kwakman received an unrestricted research grant from Servier.

Published
2018

4. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

Author

Sub Tolakker, Afd Pedagogiek in diverse samenlevingen, Methodology and statistics for the behavioural and social sciences, Kwakman, Johannes J.M., Vink, G., Vestjens, J. H., Beerepoot, L. V., de Groot, J. W., Jansen, R. L., Opdam, F. L., Boot, H., Creemers, G. J., van Rooijen, J. M., Los, M., Vulink, A. J.E., Schut, H., van Meerten, E., Baars, A., Hamberg, P., Kapiteijn, E., Sommeijer, D. W., Punt, C. J.A., Koopman, M., Sub Tolakker, Afd Pedagogiek in diverse samenlevingen, Methodology and statistics for the behavioural and social sciences, Kwakman, Johannes J.M., Vink, G., Vestjens, J. H., Beerepoot, L. V., de Groot, J. W., Jansen, R. L., Opdam, F. L., Boot, H., Creemers, G. J., van Rooijen, J. M., Los, M., Vulink, A. J.E., Schut, H., van Meerten, E., Baars, A., Hamberg, P., Kapiteijn, E., Sommeijer, D. W., Punt, C. J.A., and Koopman, M.

Published
2018

5. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

Author

Kwakman, Johannes J. M., primary, Vink, G., additional, Vestjens, J. H., additional, Beerepoot, L. V., additional, de Groot, J. W., additional, Jansen, R. L., additional, Opdam, F. L., additional, Boot, H., additional, Creemers, G. J., additional, van Rooijen, J. M., additional, Los, M., additional, Vulink, A. J. E., additional, Schut, H., additional, van Meerten, E., additional, Baars, A., additional, Hamberg, P., additional, Kapiteijn, E., additional, Sommeijer, D. W., additional, Punt, C. J. A., additional, and Koopman, M., additional

Published
2017
Full Text
View/download PDF

6. Models predicting non-sentinel node involvement also predict for regional recurrence in breast cancer patients without axillary treatment.

Author

Pepels MJ, Vestjens JH, de Boer M, Bult P, Van Dijck JA, Menke-Pluijmers M, van Diest PJ, Borm G, and Tjan-Heijnen VC

Subjects
Adult, Aged, Aged, 80 and over, Axilla pathology, Female, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Micrometastasis pathology, Neoplasm Staging, Nomograms, Risk Assessment methods, Breast Neoplasms pathology, Decision Support Techniques, Lymph Nodes pathology, Neoplasm Recurrence, Local pathology
Abstract

Background: Non-SN prediction models are frequently used in clinical decision making to identify patients that may not need axillary treatment, but these models still need to be validated by follow-up data. Our purpose was the validation of non-sentinel node (SN) prediction models in predicting regional recurrences in patients without axillary treatment., Methods: We followed a cohort of 486 women with favorable primary tumor characteristics and pN0(i+)(sn) or pN1mi(sn) for median 4.5 years. None of the patients underwent axillary treatment. Based on four published non-SN prediction models, the threshold allowing separation into low versus high-risk on non-SN involvement was set at 10%., Results: Overall 5-year regional recurrence rate was 3.0% (SE, ±0.1%). Using the Tenon scoring system, 438 low-risk patients had a 5-year regional recurrence rate of 2.3% (±0.8%), and 48 high-risk patients a recurrence rate of 10.1% (±0.4%). The MSKCC nomogram identified 300 low-risk patients with a recurrence rate of 2.8% (±1.1%), versus 166 high-risk patients with a rate of 3.4% (±0.5%) (20 patients not assessable). The Stanford nomogram identified 21 high-risk patients without recurrence, and 465 low-risk patients with a 3.2% (±0.9%) recurrence rate. A Dutch model discriminated between 384 low-risk patients with a recurrence rate of 2.2% (±0.8%) and 102 high-risk patients with a rate of 6.3% (±2.9%)., Conclusion: The Tenon scoring system outperformed the other models as it identified the largest subgroup of patients with low recurrence rate. In patients resembling our cohort we would recommend axillary treatment if they had a Tenon score above 3.5., (Copyright © 2013 Elsevier Ltd. All rights reserved.)

Published
2013
Full Text
View/download PDF

7. Blood coagulation and cancer: thrombosis and survival, clinical relevance and impact. An introduction.

Author

Vestjens JH, Sassen S, and Prins MH

Subjects
Anticoagulants adverse effects, Anticoagulants therapeutic use, Antineoplastic Agents adverse effects, Antineoplastic Agents, Hormonal adverse effects, Case-Control Studies, Catheterization, Central Venous adverse effects, Cohort Studies, Hemorrhage chemically induced, Humans, Incidence, Neoplasms complications, Neoplasms drug therapy, Neoplasms mortality, Neoplasms physiopathology, Neoplasms, Unknown Primary blood, Neoplasms, Unknown Primary diagnosis, Neoplasms, Unknown Primary epidemiology, Postoperative Complications epidemiology, Postoperative Complications physiopathology, Randomized Controlled Trials as Topic statistics & numerical data, Recurrence, Thrombophilia chemically induced, Thrombophilia drug therapy, Venous Thrombosis mortality, Venous Thrombosis physiopathology, Venous Thrombosis prevention & control, Neoplasms blood, Thrombophilia etiology, Venous Thrombosis etiology
Abstract

There is a strong association between deep venous thrombosis and cancer. In this review, we will discuss the increased incidence of cancer following an idiopathic venous thrombotic event (VTE) and the increased incidence of VTE and its recurrence in cancer patients. Furthermore, we will review the adverse impact VTE has on cancer patients' morbidity and mortality. Finally, the potential influence of anticoagulation on survival of cancer patients is discussed. Although the data are encouraging, anticoagulation is still of limited value for routine clinical practice in anticancer treatment., (Copyright 2009 S. Karger AG, Basel.)

Published
2008
Full Text
View/download PDF

8. A case of abdominal mesothelioma diagnosed by indium-III leucocyte scintigraphy.

Author

Vestjens JH, Rahnama MS, Brans BT, and Buijs J

Subjects
Abdominal Neoplasms physiopathology, Adult, Fatal Outcome, Fever of Unknown Origin etiology, Humans, Male, Mesothelioma physiopathology, Radionuclide Imaging, Weight Loss, Abdominal Neoplasms diagnostic imaging, Indium Radioisotopes, Leukocytes, Mesothelioma diagnostic imaging
Abstract

We present a case of peritoneal mesothelioma that presented with fever of unknown origin and an elevation in the inflammatory parameters. Radiological imaging did not reveal a diagnosis. Because of tumour-associated inflammatory activity, indium-III leucocyte scintigraphy enabled us to establish a diagnosis. To our knowledge, the use of indium-III leucocyte scintigraphy in peritoneal mesothelioma has not been reported previously.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results